Polo kinase is activated as cells enter mitosis and plays a central role in coordinating diverse mitotic events, yet the mechanisms leading to activation of Polo kinase are poorly understood [1] . Work in Xenopus meiotic cell cycles has suggested that Polo kinase functions in a pathway that helps trigger activation of Cdk1 [2] [3] [4] [5] . However, studies in other organisms have suggested that activation of Polo kinase is dependent upon Cdk1 and therefore occurs downstream of Cdk1 activation [6] [7] [8] . In this study, we have investigated the role of Cdk1 in the activation of budding yeast Polo kinase. The budding yeast homologs of Cdk1 and Polo kinase are referred to as Cdc28 and Cdc5. We show that signaling from Cdc28 is required to maintain Cdc5 activity in vivo. Furthermore, purified Cdc28 associated with the mitotic cyclin Clb2 is sufficient to activate purified Cdc5 in vitro. A single Cdc28 consensus phosphorylation site found at threonine 242 in the activation loop segment of Cdc5 is required for Cdc5 function in vivo and for kinase activity in vitro, whereas four other Cdc28 consensus sites are dispensable. Analysis of Cdc5 phosphorylation by mass spectrometry indicates that threonine 242 is phosphorylated in vivo. These results suggest that Cdc28 activates Cdc5 via phosphorylation of threonine 242.
Results and Discussion
To test whether Cdc28 is required for Cdc5 activity, we utilized an analog-sensitive allele of Cdc28 (Cdc28-as1) that can be rapidly and specifically inhibited in vivo by addition of the adenine analog 1NM-PP1 [9] . Cells carrying the Cdc28-as1 allele were incubated in the presence of a microtubule-destabilizing drug to arrest cells in mitosis, when Cdc5 is most active [10, 11] . The arrested cells were then treated with 1NM-PP1 and samples were taken every 5 min for 15 min. Cdc5 was immunoprecipitated from the samples and tested for its ability to phosphorylate casein. Treatment of Cdc28-as1 cells with 1NM-PP1 caused a rapid 5-fold decrease in Cdc5 activity ( Figure 1A ). Treatment of wild-type cells with the same concentration of 1NM-PP1 had no effect ( Figure 1B ). These results demonstrate that Cdc28 activity is required for the maintenance of Cdc5 activity in cells arrested in mitosis.
To examine the effects of Cdc28 inhibition on Cdc5 activity during a normal mitosis, we synchronized Cdc28-as1 cells in G1 with mating pheromone, released them synchronously into the cell cycle, and added 1NM-PP1 as the cells entered mitosis at 75 min. Samples were taken 7.5 min after 1NM-PP1 addition and Cdc5 kinase activity was assayed. After 7.5 min of Cdc28 inhibition, Cdc5 kinase activity was reduced 6-fold relative to a mock-treated control ( Figure 1C , compare lanes 2 and 3). Note that the cells were still undergoing entry into mitosis and Cdc5 activity was therefore rising at the time of 1NM-PP1 addition. As a result, the mock-treated control has greater Cdc5 kinase activity than the initial time point. These results demonstrate that Cdc28 activity is required for Cdc5 activity during a normal mitosis.
We next tested whether Cdc28 can directly activate Cdc5. Since Cdc28 associates with the mitotic cyclin Clb2 to promote entry into mitosis, we tested whether purified Cdc28/Clb2 complexes can activate purified Cdc5 in vitro. An inactive form of Cdc5 was created by immunoprecipitating Cdc5 from cells arrested in mitosis, followed by treatment with lambda phosphatase. The phosphatase treatment eliminated Cdc5-associated kinase activity, and addition of purified Cdc28/ Clb2 complexes in the presence of ATP restored Cdc5 kinase activity to untreated levels ( Figure 1D , lanes 1, 2, 3, and 6). A systematic screen for substrates of Clb2/Cdc28 complexes independently identified Cdc5 as a potential target of Cdc28/Clb2 [12] .
Cdc5 has one strict Cdc28-consensus site (S/T-P-X-K/R) and four minimal sites (S/T-P). We therefore made single mutants that change each of these residues to a nonphosphorylatable alanine and assayed their ability to rescue a loss of CDC5 function. The mutants were expressed from the endogenous CDC5 promoter in a strain that is dependent upon a single copy of CDC5 expressed from the GAL1 promoter. Four of the mutants were able to support viability when cells were grown in the presence of dextrose to turn off expression of wildtype CDC5; however, cells carrying the cdc5-T242A allele as their sole source of Cdc5 were inviable and exhibited a late mitotic arrest similar to the arrest caused by temperature-sensitive alleles of CDC5 (Figure 2A and data not shown).
Threonine 242 is conserved in all Polo kinases and is located within a region of the kinase domain that comprises an ''activation loop'' in many kinases ( Figure 2B ) [13] . Phosphorylation of residues within this activation loop is often required for activation of kinases. We therefore asked whether the cdc5-T242A mutation eliminated kinase activity in vitro. As shown in Figure 2C , the cdc5-T242A allele eliminated Cdc5 kinase activity to the same extent as a kinase-dead cdc5-K110A allele. Threonine 242 is therefore required for Cdc5 function in vivo and for kinase activity in vitro. We next generated a mutant version of CDC5 in which all four of the nonessential consensus sites were mutated to alanine (cdc5-4A). We found that Cdc5-4A was activated by Cdc28/Clb2 *Correspondence: kellogg@biology.ucsc.edu to levels similar to wild-type Cdc5 ( Figure 1D , compare lanes 3 and 5). The cdc5-4A allele was also able to rescue the cdc5-1 temperature-sensitive allele when expressed from the GAL1 promoter (data not shown). In contrast, Cdc5-T242A could not be reactivated by Cdc28 after treatment with phosphatase ( Figure 1D , lane 4). These results suggest that Cdc28 can stimulate Cdc5 kinase activity through phosphorylation of threonine 242.
To determine whether T242 is phosphorylated in vivo and to identify other phosphorylated residues, we used immunoaffinity chromatography to isolate Cdc5 from cells arrested in mitosis and mapped phosphorylation sites by mass spectrometry. This analysis identified ten phosphorylation sites, including T242 ( Figure 3 ). The analysis also revealed that a neighboring threonine is phosphorylated (T238). Previous work reported that the threonine corresponding to T238 is also phosphorylated in Xenopus and mammalian cells; however, the function of this phosphorylation is controversial. In one case, it was found that mutation of the corresponding threonine to an alanine caused a slight reduction in Polo kinase activity in vitro [14] . A second study found that changing the threonine to a valine caused a complete loss of kinase activity [15] . We mutated T238 to an alanine but observed no phenotype, which suggests that T238 phosphorylation is not strictly required for Cdc5 activity in vivo. We also individually mutated the other phosphorylation sites identified by mass spectrometry and assayed their ability to support viability in the absence of wild-type Cdc5 (not shown). Of the nine phosphorylation site mutants that we tested, only threonine 242 was required for Cdc5 function. We have not yet tested whether S73 is required for viability.
Taken together, our results suggest that Cdc28 plays an important and direct role in activation of Cdc5 kinase activity. The finding that Cdc5 is downstream of Cdc28 in budding yeast is consistent with the fact that temperature-sensitive cdc5 mutants arrest in late mitosis [10, 16] . To further test whether Cdc5 might act upstream of Cdc28, we used mitotic spindle assembly as a marker for entry into mitosis and determined whether the cdc5-1 Figure 1 . Cdc28 Is Required for Cdc5 Activity In Vivo and Can Activate Cdc5 In Vitro (A) cdc28-as1 CDC5-3XHA cells were arrested in mitosis with nocodazole, 25 mM 1NM-PP1 was added, and time points were taken every 5 min. Cdc5-3XHA was immunoprecipitated and kinase activity was assayed by phosphorylation of casein (bottom). Levels of immunoprecipitated Cdc5-3XHA were monitored by Western blotting (top). (B) A control showing that treatment of wildtype cells with 1NM-PP1 had no effect on Cdc5-3XHA activity. Wild-type Cdc28 cells were arrested in mitosis with nocodazole, 25 mM 1NM-PP1 was added, and a sample was taken 15 min later. Cdc5-3XHA was immunoprecipitated and kinase activity was assayed by phosphorylation of casein. (C) Cdc28 is required for Cdc5 activity in a normal cell cycle. cdc28-as1 cells were arrested in G1 with a factor and released synchronously into the cell cycle. An initial time point was taken at 75 min as the cells were entering mitosis (lane 1). Identical aliquots of cells were then treated with 25 mM 1NM-PP1 or with DMSO and samples were taken after 7.5 min. Cdc5-3XHA was immunoprecipitated from each sample and kinase activity was assayed by phosphorylation of casein (bottom). The lane marked ''Control'' corresponds to the sample mock-treated with DMSO. (D) Activation of Cdc5 by Cdc28/Clb2 in vitro. Wild-type or mutant versions of Cdc5-3XHA were immunoprecipitated from cells arrested in mitosis and incubated in the presence or absence of lambda phosphatase. After washing away the phosphatase, Cdc5-3XHA was incubated in the presence or absence of Cdc28/Clb2 and ATP. Kinase assays were then performed on each sample using casein as a substrate. Cdc5-3XHA protein levels were monitored by Western blotting (top), and kinase activity was assayed by phosphorylation of casein (bottom).
temperature-sensitive allele shows delayed entry into mitosis. We observed no delay, which further suggests that Cdc5 does not act upstream of mitotic Cdc28 in budding yeast (data not shown). Previous work has shown that Cdc5 activity is exactly correlated with Clb2/Cdc28 activity in vivo, which further supports the idea that Clb2/Cdc28 activates Cdc5 [10] . Our results suggest that phosphorylation of T242 provides the major contribution to activation of Cdc5; however, we cannot rule out the possibility that additional phosphorylations contribute to Cdc5 activation in vivo.
In contrast to our results in budding yeast, previous studies carried out in Xenopus meiotic cells suggested that Polo kinase functions upstream of Cdk1 as a regulator of the Cdc25 phosphatase. In these experiments, it was found that Polo kinase can bind, phosphorylate, and activate Cdc25, which triggers activation of Cdk1 [4, 5] . In addition, immunodepletion of Polo kinase blocks activation of Cdc25 and entry into mitosis [4] . However, work in other cell types suggested that Polo kinases may not act upstream of Cdk1. For example, inhibition of Polo kinase in mammalian cells with siRNA had no effect on entry into mitosis or activation of Cdk1 [17, 18] . Similarly, experiments in fission yeast have suggested that Polo kinase activation is downstream of Cdk1 [6] . A role for Polo kinases upstream of Cdk1 may be unique to Xenopus meiotic cells. It is also possible that Polo kinases act both upstream and downstream of Cdk1 and that the relative importance of the upstream role of Polo kinases varies between cell types. Further work will be necessary to determine the mechanisms that ensure proper spatial and temporal regulation of Cdc5/Polo kinase activity during mitosis.
Experimental Procedures Yeast Plasmid and Strain Construction
The CDC5 gene was amplified from yeast genomic DNA and cloned into the EcoR1 and BamH1 sites in Ycplac22 to generate pEM110 (oligos GCGGAATTCCTGAGAAAGTAAATCCAATTC and 3 0 -GCGG GATCCAACGCTATATGAGAACTATTG). An integrating vector containing Cdc5-3XHA under the control of the GAL1 promoter was generated by cloning CDC5 into the BamH1 and Eag1 sites in pSH32 to produce pEM120 (oligos 5 0 -GCGGGATCCATGTCGTTGG GTCCTCTTAAA and GCGCGGCCGATCTACGGTAACAATTGTGG). This plasmid was cut with Stu1 to integrate GAL1-CDC5-3XHA at the URA3 locus. The following plasmids carrying mutant versions of CDC5 were created by mutagenesis of pEM120: pEM121
T242A -3XHA), and
The following plasmids were generated by mutagenesis of pEM110: pEM130 (encoding Cdc5 T23A ),
), and pEM142 (Cdc5 T423A ). All strains were created in the W303 background (leu2-3,112 ura3-52 can1-100 ade2-1 his3-11 trp1-11). The additional features of the strains used in this study are listed: EM42: CDC5-3XHA::HIS5, Cdc28-as1; EM54: CDC5-3XHA::HIS5; EM55: GAL1-CDC5-3XHA:: URA3 (pEM120); EM56: GAL1-CDC5-K110A-3XHA::URA3 (pEM121); EM57: GAL1-CDC5-T242A-3XHA::URA3 (pEM122); EM58: GAL1-CDC5-4A-3XHA::URA3 (pEM126); EM61: GAL1-CDC5::URA3, CDC5T23A::TRP1 (pEM130); EM62: GAL1-CDC5::URA3, CDC5T70A::TRP1 (pEM131); EM63: GAL1-CDC5::URA3, CDC5T 242A::TRP1 (pEM132); EM64: GAL1-CDC5::URA3, CDC5S419A::TRP1 (pEM133); EM65: GAL1-CDC5::URA3, CDC5S657A::TRP1 (pEM134); EM66: GAL1-CDC5::URA3, CDC5S2A::TRP1 (pEM136); EM67: GAL1-CDC5::URA3, CDC5S18A::TRP1 (pEM137); EM68: GAL1-CDC5::URA3, CDC5T29A::TRP1 (pEM138); EM69: GAL1-CDC5::URA3, CDC5S119A::TRP1 (pEM139); EM70: GAL1-CDC5::URA3, CDC5T 238A::TRP1 (pEM140); EM71: GAL1-CDC5::URA3, CDC5S417A::TRP1 (pEM141); EM72: GAL1-CDC5::URA3, CDC5T423A::TRP1 (pEM142). (C) Wild-type CDC5, cdc5-K110A, and cdc5-T242A were expressed as 3XHA fusion proteins from the GAL1 promoter in cells arrested in mitosis with benomyl. The kinases were immunoprecipitated and assayed for kinase activity by phosphorylation of casein (bottom), and Cdc5-3XHA protein levels in the immunoprecipitates were monitored by Western blotting (top).
Cell Cycle Arrests, In Vitro Kinase Assays, Western Blotting, and Treatment with Phosphatase and 1NM-PP1 To examine the effects of Cdc28 inhibition on Cdc5 kinase activity ( Figures 1A and 1B) , strains EM42 and EM54 were grown overnight in YPD to an optical density of 0.5 and arrested in mitosis by incubation in YPD containing 30 mg/ml benomyl for 2 hr, followed by treatment with 25 mm 1NM-PP1. The cells from 25 ml of culture were used for each kinase assay. Extracts for kinase assays were made as described previously [19] . Cdc5-3XHA immunoprecipitations for kinase assays were carried out in the presence of a high salt buffer to remove associated proteins (IP buffer: 50 mM HEPES-KOH [pH 7.6], 1 M KCl, 50 mM b-glycerophosphate, 50 mM NaF, 1 mM EGTA, 1 mM MgCl 2 , 0.15% Tween-20, 10% glycerol, 1 mM PMSF). All immunoprecipitations were performed as described previously via a polyclonal HA antibody [19] . Kinase reactions were performed by incubating immunoprecipitated Cdc5-3XHA in 20 ml kinase assay buffer (50 mM HEPES-KOH [pH 7.6], 1 mM EGTA, 2 mM MgCl 2 , 0.1% Tween-20, 10% glycerol, 1 mM dithiothreitol) supplemented with 0.25 mM ATP, 0.1 ml [g-32 P]ATP and 5 mg casein. Kinase reactions were incubated for 30 min at 30ºC. Reactions were terminated by the addition of 43 sample buffer and run on 11% SDS-PAGE gels [20] .
For reactivation of phosphatase-treated Cdc5 by Cdc28/Clb2 ( Figure 1C ), strains containing wild-type or mutant versions of Cdc5-3XHA under the control of the galactose promoter (strains EM55, EM56, EM57, EM58) were grown overnight in YEP + 2% raffinose to exponential phase. Galactose was then added to 2% and cells were incubated for 2 hr at room temperature prior to the addition of nocodazole to 20 mg/ml. Immunoprecipitated Cdc5-3XHA was treated with 1.5 ml l phosphatase (New England Biolabs) for 30 min followed by three washes with IP buffer and three washes with kinase assay buffer. After the final wash, 20 ml kinase buffer supplemented with 1 mM ATP was added along with w.25 ng of purified Cdc28/Clb2-3XHA. The reaction was incubated for 30 min at 30ºC and was then washed three times with IP buffer; Cdc5 kinase activity was then assayed as described above. Cdc28/Clb2-3XHA complexes were purified as previously described [21] .
Mapping of Cdc5 Phosphorylation Sites
Cells containing a 3XHA-tagged copy of Cdc5 under the control of the endogenous promoter were grown overnight at 30ºC to OD 600 0.5 overnight and then arrested in mitosis by incubating in YPD + 30 mg/ml benomyl for 2 hr. The cells were pelleted, resuspended in 50 mM HEPES-KOH [pH 7.6], transferred to a 50 ml tube, pelleted again, and frozen in liquid nitrogen. Cells were lysed by grinding with a mortar and pestle under liquid nitrogen. 10 g of cell powder was resuspended in 20 ml of lysis buffer (50 mM HEPES-KOH [pH 7.6], 1 M KCl, 50 mM b-glycerophosphate, 50 mM NaF, 1 mM EGTA, 1 mM MgCl 2 , 0.25% Tween-20, 5% glycerol, 1 mM PMSF). The extract was then centrifuged for 5 min at 10,000 3 g, followed by 100,000 3 g for 45 min. The clarified extract was incubated with 500 mg affinity-purified anti-HA antibody coupled to 500 ml protein A agarose for 2 hr at 4ºC. The beads were then pelleted and washed 23 with 15 ml of lysis buffer and transferred to a column. The column was washed with 5 ml of lysis buffer before eluting Cdc5-3XHA in 50 mM HEPES-KOH (pH 7.6), 200 mM KCl, 1 mM EGTA, 1 mM MgCl 2 , 10% glycerol, supplemented with 0.5 mg/ml HA dipeptide. The elution was TCA precipitated and run on a 10% polyacrylamide gel. The Cdc5-3XHA band was excised and the protein was in-gel reduced, alkylated, and digested with trypsin [22] . The peptide mixture was analyzed by nanoscale-microcapillary reversed phase liquid chromatography tandem mass spectrometry (LC-MS/MS) [23] by a Finnigan LTQ linear quadrupole ion trap, or a Finnigan LTQ FT linear quadrupole ion trap/Fourier transform ion cyclotron resonance mass spectrometer (Thermo Electron). MS/MS spectra were searched against the Cdc5 protein sequence with the SEQUEST search algorithm, applying no constraints regarding enzyme specificity and allowing serine, threonine, and tyrosine residues to be phosphorylated [24] . Assignments of MS/MS spectra to tryptic phosphopeptides were validated manually with special consideration of fragment ions formed through neutral loss of phosphoric acid [25] . The mapping was carried out twice on two independently isolated samples, with equivalent results.
